Susquehanna International Group, LLP Hepion Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	SELL	$0.31 - $1.06 $6,231 - $21,306	-20,100 Reduced 35.2%	37,000 $28,000
Q4 2022 Feb 14, 2023	BUY	$0.27 - $11.9 $837 - $36,890	3,100 Added 5.74%	57,100 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $17,697 - $360,880	-34,700 Reduced 39.12%	54,000 $28,000
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.22 $73,302 - $156,892	-128,600 Reduced 59.18%	88,700 $51,000
Q1 2022 May 16, 2022	BUY	$0.93 - $1.29 $77,655 - $107,715	83,500 Added 62.41%	217,300 $280,000
Q4 2021 Feb 14, 2022	SELL	$1.14 - $1.58 $351,689 - $487,430	-308,500 Reduced 69.75%	133,800 $153,000
Q3 2021 Nov 15, 2021	BUY	$1.39 - $2.1 $368,072 - $556,080	264,800 Added 149.18%	442,300 $677,000
Q2 2021 Aug 11, 2021	SELL	$1.56 - $2.26 $276,120 - $400,019	-177,000 Reduced 49.93%	177,500 $351,000
Q1 2021 May 17, 2021	BUY	$1.77 - $2.98 $436,305 - $734,570	246,500 Added 228.24%	354,500 $652,000
Q4 2020 Feb 16, 2021	BUY	$1.58 - $3.64 $142,990 - $329,420	90,500 Added 517.14%	108,000 $237,000
Q3 2020 Nov 16, 2020	BUY	$2.84 - $4.59 $49,700 - $80,325	17,500 New	17,500 $54,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $35.1M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.